Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours

PURPOSE: This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid tumours. The pharmacokinetic profile and antitumour activity of olaparib tablets...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Autores principales: Yonemori, Kan, Tamura, Kenji, Kodaira, Makoto, Fujikawa, Koshi, Sagawa, Tamotsu, Esaki, Taito, Shirakawa, Tsuyoshi, Hirai, Fumihiko, Yokoi, Yuki, Kawata, Toshio, Hatano, Ben, Takahashi, Yasuo
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5010592/
https://ncbi.nlm.nih.gov/pubmed/27422301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3106-7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares